A BridgeBio Pharma drug developed for an more and more frequent cardiovascular situation has obtained FDA approval, marking a comeback for an organization and a molecule with a turbulent historical past. However BridgeBio's challenges will not be over but. The biotech's new product should now compete with a blockbuster drug from Pfizer that’s already well-established as a typical of care […]